Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Conditions: Acute Lung Injury; Acute Respiratory Distress Syndrome; Sepsis

What is the purpose of this trial?

This is a prospective, randomized (1:1), double-blind, multi-center, Phase II clinical study to test the safety and efficacy of a recombinant chimeric anti-tissue factor antibody (ALT-836) versus placebo in patients with sepsis and acute lung injury/acute respiratory distress syndrome (ALI/ARDS).

Dates: April 2009 -
Study Status: Recruiting

Who can participate?

Ages Eligible: 18 Years and older
Gender Eligible: Both

INCLUSION CRITERIA:

1. Suspected or proven infection

2. Hypoxemia: PaO2/FiO2is =300 mm Hg

3. Bilateral infiltrates consistent with pulmonary edema

4. Positive-pressure mechanical ventilation through an endotracheal tube

5. No clinical evidence of left atrial hypertension to explain bilateral infiltrates

6. Presence of at least three of the four SIRS criteria. If only two criteria are
evidenced, one must be temperature or WBC

Criteria 2 and 3 must occur within a 24-hour interval. The 48-hour enrollment time window
begins when criteria 2, 3, and 4 are met.

EXCLUSION CRITERIA:

1. <18 years

2. Inability to obtain consent

3. Patient, surrogate, or physician not committed to full support

4. Moribund state in which death was perceived to be imminent

5. Morbid obesity

6. Malignancy or other irreversible disease or condition for which 6-month mortality is
estimated to be >50%

7. Known HIV positive with known end stage processes

8. Prior cardiac arrest requiring CPR without fully demonstrated neurological recovery;
or New York Heart Association Class IV

9. Pregnant or nursing

10. Mechanically or chemically-induced ALI/ARDS (including burns, trauma, and near
drowning)

11. >48 hours since all inclusion criteria are met

12. Neuromuscular disease that impairs ability to ventilate without assistance

13. Severe chronic respiratory disease, severe pulmonary hypertension, or ventilator
dependency

14. Chest wall deformity resulting in severe exercise restriction, secondary
polycythemia, or respirator dependent

15. History of organ transplant (including bone marrow)

16. Severe chronic liver disease, as determined by a Child-Pugh Score >10

17. Hemoglobin persistently < 8.0 g/dL

18. Platelet count <50,000/mm3

19. Prolonged INR >3

20. Bleeding disorders unless corrective surgery has been performed

21. Active internal bleeding

22. Major surgery within 48 hours before study drug infusion, or evidence of active
bleeding postoperatively, or plan for any major surgery within 3 days after study
drug infusion.

23. Diffuse alveolar hemorrhage from vasculitis

24. Known bleeding diathesis

25. Presence of an epidural catheter or lumbar puncture within 48 hours before study drug
infusion or anticipation of receiving an epidural catheter or a lumbar puncture
within 48 hours after study drug infusion

26. Stroke within 3 months of study entry

27. Trauma with an increased risk of life-threatening bleeding

28. A history of severe head trauma that required hospitalization, or intracranial
surgery within two months of study entry

29. Any history of intracerebral arteriovenous malformation, cerebral neurysm, or central
nervous system mass lesion

30. Uses of certain medications or treatment regimens such as chemotherapy,
unfractionated heparin, low-molecular-weight heparin, Warfarin, antithrombin III,
acetylsalicylic acid, glycoprotein IIb/IIIa antagonists, thrombolytic therapy, and
activated Protein C are restricted.

31. Participation in another experimental medication study within 30 days of study entry
with the exception of the ARDSNet pharmaconutrient nutrition trial (OMEGA)

32. Any prior treatment with a murine or chimeric antibody.